Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)

Details for Australian Patent Application No. 2005329398 (hide)

Owner The Trustees of Columbia University in the City of New York

Inventors Deng, Shixian; Marks, Andrew R.; Landry, Donald W.; Cheng, Zhen Zhuang

Agent Spruson & Ferguson

Pub. Number AU-A-2005329398

PCT Pub. Number WO2006/101496

Priority 11/088,058 23.03.05 US

Filing date 24 March 2005

Wipo publication date 28 September 2006

International Classifications

C07D 281/02 (2006.01) Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms

Event Publications

4 October 2007 PCT application entered the National Phase

  PCT publication WO2006/101496 Priority application(s): WO2006/101496

25 March 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005329399-Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)

2005329385-Display merchandiser with lighting enhancement